Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases

• Published in: Rheumatology and therapy. 2023-02, Vol.10 (1), p.201-223
• Main Authors: Salinas, Claudia A., Louder, Anthony, Polinski, Jennifer, Zhang, Tancy C., Bower, Hannah, Phillips, Syd, Song, Yufei, Rashidi, Emaan, Bosan, Rafia, Chang, Hsiu-Ching, Foster, Nicole, Gershenson, Bernice, Yamanaka, Hisashi, Kishimoto, Mitsumasa, Tanaka, Yoshiya, Fischer, Peter, Zhu, Baojin, Faries, Douglas, Mai, Xiaodan, Doherty, Brett T., Grelaud, Angela, Thurin, Nicolas H., Askling, Johan, Deberdt, Walter
• Format: Article
• Language: English
• Subjects: Baricitinib; Biological products; Epidemiology; Family Medicine; General Practice; Infections; Insurance claims; Internal Medicine; JAK inhibitors; Major adverse cardiovascular event; Medicin och hälsovetenskap; Medicine; Medicine & Public Health; Original Research; Orthopedics; Patients; Quality of Life Research; Rheumatoid arthritis; Rheumatology; Serious infection; Thromboembolism; Tumor necrosis factor-TNF; Venous thromboembolism
• ISSN: 2198-6576; 2198-6584
• DOI: 10.1007/s40744-022-00505-1

Introduction The aim of this work is to evaluate baricitinib safety with respect to venous thromboembolism (VTE), major adverse cardiovascular events (MACE), and serious infection relative to tumor necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA). Methods Patients with RA from 14 real-world data sources (three disease registries, eight commercial and three government health insurance claims databases) in the United States ( n  = 9), Europe ( n  = 3), and Japan ( n  = 2) were analyzed using a new user active comparator design. Propensity score matching (1:1) controlled for potential confounding. Meta-analysis of incidence rate ratios (IRR) and incidence rate differences (IRD) for each outcome, from each data source was executed using modified Poisson regression and Cochran–Mantel–Haenszel analysis. Results Of 9013 eligible baricitinib-treated patients, 7606 were propensity score-matched with TNFi-treated patients, contributing 5879 and 6512 person-years of baricitinib and TNFi exposure, respectively. Across data sources, 97 patients (56 baricitinib) experienced VTE during follow-up, 93 experienced MACE (54 baricitinib), and 321 experienced serious infection (176 baricitinib). Overall IRRs comparing baricitinib with TNFi treatment were 1.51 (95% CI 1.10, 2.08) for VTE, 1.54 (95% CI 0.93, 2.54) for MACE, and 1.36 (95% CI 0.86, 2.13) for serious infection. IRDs for VTE, MACE, and serious infection, respectively, were 0.26 (95% CI −0.04, 0.57), 0.22 (95% CI −0.07, 0.52), and 0.57 (95% CI −0.07, 1.21) per 100 person-years greater for baricitinib than TNFi. Conclusions Overall results suggest increased risk of VTE with baricitinib versus TNFi, with consistent point estimates from the two largest data sources. A numerically greater risk was observed for MACE and serious infection when comparing baricitinib versus TNFi, with different point estimates from the two largest data sources. Findings from this study and their impact on clinical practice should be considered in context of limitations and other evidence regarding the safety and efficacy of baricitinib and other Janus kinase inhibitors. Trial registration: EU PAS Register ( http://encepp.eu ), identifier #32271.